Bringing together talented scientists, experienced leaders and innovative entrepreneurs.

Learn More

Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.

Learn More

Building a robust pipeline of oncology and orphan drugs focused in multiple indications.

Learn More

Developing powerful drugs to protect from radiation.

Learn More

       

Product Portfolio

Our pipeline includes several novel clinical-stage drug candidates for cancer treatment and protection from lethal radiation.

View Our Product Portfolio

Our most advanced product candidate is entolimod (CBLB502), which we are developing for a biodefense indication and as an oncology drug.

entolimod (CBLB502) Biodefense entolimod (CBLB502) Oncology

Clinical Trials

We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.

Enrollment is open for our therapeutic clinical trials for various indications with oncology drug candidates in the pipeline.

Learn More about our Phase 1 oncology studies with entolimod (CBLB502) Learn More about Incuron’s Phase 1 oncology studies with CBL0137

Recent News

Read All News

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue